Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SEC inquiry

Executive Summary

Bristol "continues to believe that its accounting treatment of domestic wholesaler build-up has been completely appropriate," CEO Peter Dolan declares. The company specifically discussed its treatment of Medicaid accrual rates associated with the wholesaler inventory issues before recording a special charge for that amount in first quarter earnings, Dolan says (1"The Pink Sheet" April 29, p. 15)...
Advertisement

Related Content

Bristol Revises Product Overstocking Impact With $262 Mil. Medicaid Accrual
Bristol Revises Product Overstocking Impact With $262 Mil. Medicaid Accrual
Advertisement
UsernamePublicRestriction

Register

PS040240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel